{
    "nct_id": "NCT06698042",
    "official_title": "A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS 50% or Greater",
    "inclusion_criteria": "* Histologically or cytologically confirmed diagnosis of squamous or nonsquamous non-small cell lung cancer (NSCLC).\n* Measurable disease as assessed by the local site investigator/radiology.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements.\n* Received prior systemic anticancer therapy for their metastatic NSCLC.\n* Known additional malignancy that is progressing or has required active treatment within the past 3 years.\n* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.\n* Active autoimmune disease that has required systemic treatment in the past 2 years.\n* History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.\n* Active infection requiring systemic therapy.",
    "miscellaneous_criteria": ""
}